Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections

References

• Uncomplicated and complicated skin and skin structure infections-developing antimicrobial drugs for treatment. Washington, DC: U.S. Department of Health and Human Services, 1998; Available from http://www.fda.gov/cder/guidance/2566dft.pdf [Last accessed 2007 June 8]
   Google Scholar
• Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 2005;6:283–95
   Google Scholar
• National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470–85
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436–44
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355: 666–74
   PubMed Web of Science ®Google Scholar
• Segreti J. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance. Clin Microbiol Infect 2005;11(Suppl 3):29–35
   PubMed Web of Science ®Google Scholar
• Nathwani D. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? J Antimicrob Chemother 2003;51(Suppl 2):ii37–44
   Google Scholar
• Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45: 1919–22
   Google Scholar
• Fuchs PC, Barry AL, Brown SD. Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media. J Antimicrob Chemother 2001;48:557–61
   Google Scholar
• King A, Phillips I. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J Antimicrob Chemother 2001;48:219–23
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Bradford PA, Weiss WJ, et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002;46:2595–601
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Hershberger E, Moldovan T, et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristindalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob Agents Chemother 2000;44:1062–6
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA, et al. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 2000;44:3447–50
   PubMed Web of Science ®Google Scholar
• Wise R, Andrews JM, Ashby JP. Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001;48:563–7
   Google Scholar
• Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002;49:467–70
   Web of Science ®Google Scholar
• Cubicin® (daptomycin for injection). Full Prescribing Information: Cubist Pharmaceuticals, Inc. Lexington, MA, USA, 2006
   Google Scholar
• Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673–81
   PubMed Web of Science ®Google Scholar
• Owens R, Lamp KC, Russo R, et al. Post marketing experience with daptomycin (DAP) for the treatment of skin and skin structure infections (SSSI). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. December 16–19, 2005. Washington, DC, USA, 2005
   Google Scholar
• Brown J, Lamp KC, Friedrich LV. Efficacy and safety of daptomycin (DAP) for the treatment of skin and skin structure infections (SSSI). Third International Symposium on Resistant Gram-Positive Infections. October 9–11, 2006. Niagara-on-the-Lake, ON, Canada, 2006
   Google Scholar
• Hall L, Rybak MJ, Davis S, et al. Methicillin-resistant Staphylococcusaureus complicated skin and soft tissue infection: assessment of daptomycin versus vancomycin. Annual Meeting of the American College of Clinical Pharmacy. October 26–29, 2006. St. Louis, MO, USA, 2006
   Google Scholar
• Matthews P, Deburn M. Faster resolution of clinical signs (CSx) in complicated skin and soft tissue infections (cSST) by daptomycin (DAP) vs. standard therady (STND) in a randomized, blinded, comparative study (DAP-99–01). Infectious Diseases Society of America 39th Annual meeting. October 25–28, 2001. San Francisco, CA, USA, 2001
   Google Scholar
• Davis S, Rybak MJ, Delgado G, et al. Clinical and economic outcomes of daptomycin versus vancomycin for complicated skin-skin structure infections. Infectious Disease Society of America 44th Annual Meeting. October 12–15, 2006. Toronto, ON, Canada, 2006
   Google Scholar
• Davis S, McKinnon P. Daptomycin reduces time to successful treatment of complicated skin and skin structure infections when compared with vancomycin or semi synthetic penicillins. Infectious Diseases Society of America 42nd Annual Meeting. September 14–17, 2004. Boston, MA, USA, 2004
   Google Scholar
• Alborn WE Jr., Allen NE, Preston DA. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 1991;35:2282–7
   PubMed Web of Science ®Google Scholar
• Allen NE, Alborn WE Jr., Hobbs JN Jr. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother 1991;35:2639–42
   Google Scholar
• Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:2538–44
   Google Scholar
• Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy 2004;24:41–57
   PubMed Web of Science ®Google Scholar
• Silverman JA, Harris B, Cortroneo N, et al. Daptomycin treatment induces membrane and cell-wall alterations in Staphylococcusaureus. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. September 14–17, 2003. Chicago, IL, USA, 2003
   Google Scholar
• Lamp KC, Rybak MJ, Bailey EM, et al. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 1992;36:2709–14
   PubMed Web of Science ®Google Scholar
• Mascio C, Silverman JA, Alder J. Bactericidal action of daptomycin (DAP) against non-dividing Staphylococcusaureus. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. December 16–19, 2005. Washington, DC, USA, 2005
   Google Scholar
• LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004;48:4665–72
   PubMed Web of Science ®Google Scholar
• Gardner SE, Frantz RA, Doebbeling BN. The validity of the clinical signs and symptoms used to identify localized chronic wound infection. Wound Repair Regen 2001;9:178–86
   Google Scholar
• Gardner SE, Frantz RA, Troia C, et al. A tool to assess clinical signs and symptoms of localized infection in chronic wounds: development and reliability. Ostomy Wound Manage 2001;47:40–7
   PubMedGoogle Scholar
• Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006;442:39–44
   Google Scholar
• Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005;17:338–44
   PubMed Web of Science ®Google Scholar
• English BK, Maryniw EM, Talati AJ, et al. Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin. Antimicrob Agents Chemother 2006;50:2225–7
   PubMed Web of Science ®Google Scholar
• Nathwani D. The management of skin and soft tissue infections: outpatient parenteral antibiotic therapy in the United Kingdom. Chemotherapy 2001;47(Suppl 1):17–23
   PubMed Web of Science ®Google Scholar
• Vinken AG, Li JZ, Balan DA, et al. Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals. Am J Ther 2003;10:264–74
   PubMedGoogle Scholar
• Siegel RE, Alicea M, Lee A, et al. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. Am J Ther 1999;6: 217–22
   PubMedGoogle Scholar
• Innes HE, Smith DB, O’Reilly SM, et al. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 2003;89:43–9
   Google Scholar
• Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003;124:526–35
   Google Scholar
• Wilson SE, Solomkin JS, Le V, et al. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am J Surg 2003;185:369–75
   PubMed Web of Science ®Google Scholar
• Alberti C, Brun-Buisson C, Goodman SV, et al. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med 2003;168:77–84
   PubMed Web of Science ®Google Scholar
• Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004;64:1621–42
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373–406
   PubMed Web of Science ®Google Scholar
• Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006;50: 1372–5
   PubMed Web of Science ®Google Scholar